Nowadays, the treatment landscape of NSCLC includes target therapy, immunotherapy, and combination therapy, which is mainly decided by the patients’ driver genes status, especially EGFR and ALK (Grant et al., 2021). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.